Skip to main content
. 2023 Sep 3;153(11):3247–3258. doi: 10.1016/j.tjnut.2023.08.031

TABLE 2.

Hazard ratios (95% CIs) of CVD incidence according to dietary glutamine and glutamate consumption after diabetes diagnosis

Dietary glutamine intake
Q1 (Low) Q2 Q3 Q4 Q5 (High) P-trend
CVD
No. of case/person-y 654/39,102 531/39,455 590/39,375 551/39,513 601/39,413
Model 1 1 0.83 (0.74, 0.94) 0.91 (0.81, 1.02) 0.82 (0.73, 0.93) 0.84 (0.75, 0.95) 0.003
Model 2 1 0.87 (0.77, 0.98) 0.94 (0.84, 1.06) 0.87 (0.77, 0.99) 0.88 (0.77, 0.99) 0.04
CHD
No. of case/person-y 511/39,102 418/39,455 449/39,375 423/39,513 474/39,413
Model 1 1 0.83 (0.73, 0.95) 0.87 (0.76, 0.99) 0.79 (0.69, 0.91) 0.83 (0.73, 0.95) 0.003
Model 2 1 0.87 (0.76, 1.00) 0.90 (0.79, 1.03) 0.84 (0.73, 0.97) 0.87 (0.75, 1.00) 0.04
Stroke
No. of case/person-y 143/39,102 113/39,455 141/39,375 128/39,513 127/39,413
Model 1 1 0.84 (0.65, 1.09) 1.07 (0.83, 1.36) 0.95 (0.74, 1.22) 0.89 (0.69, 1.15) 0.46
Model 2
1
0.87 (0.67, 1.13)
1.11 (0.86, 1.42)
0.98 (0.76, 1.27)
0.93 (0.71, 1.22)
0.71
Dietary glutamate intake


Q1 (Low)
Q2
Q3
Q4
Q5 (High)
P-trend
CVD
No. of case/person-y 557/39,286 550/39,516 535/39,552 562/39,504 723/39,000
Model 1 1 1.06 (0.94, 1.20) 1.07 (0.94, 1.21) 1.15 (1.01, 1.30) 1.44 (1.28, 1.61) <0.0001
Model 2 1 1.07 (0.95, 1.21) 1.05 (0.92, 1.18) 1.11 (0.98, 1.26) 1.30 (1.15, 1.46) <0.0001
CHD
No. of case/person-years 424/39,286 421/39,516 407/39,552 447/39,504 576/39,000
Model 1 1 1.07 (0.93, 1.22) 1.06 (0.92, 1.23) 1.21 (1.05, 1.39) 1.50 (1.31, 1.71) <0.0001
Model 2 1 1.07 (0.93, 1.23) 1.03 (0.90, 1.19) 1.16 (1.00, 1.33) 1.32 (1.15, 1.51) <0.0001
Stroke
No. of case/person-years 133/39,286 129/39,516 128/39,552 115/39,504 147/39,000
Model 1 1 1.06 (0.82, 1.35) 1.07 (0.83, 1.37) 0.96 (0.74, 1.25) 1.22 (0.96, 1.56) 0.12
Model 2
1
1.07 (0.84, 1.38)
1.07 (0.83, 1.38)
0.96 (0.74, 1.25)
1.20 (0.93, 1.55)
0.22
Dietary glutamine-to-glutamate ratio


Q1 (Low)
Q2
Q3
Q4
Q5 (High)
P-trend
CVD
No. of case/person-years 659/39,065 579/39,420 528/39,582 604/39,418 557/39,374
Model 1 1 0.87 (0.77, 0.97) 0.78 (0.69, 0.87) 0.87 (0.78, 0.97) 0.77 (0.69, 0.86) <0.0001
Model 2 1 0.94 (0.84, 1.05) 0.86 (0.77, 0.97) 0.96 (0.86, 1.07) 0.84 (0.75, 0.95) 0.01
CHD
No. of case/person-years 510/39,065 444/39,420 421/39,582 462/39,418 438/39,374
Model 1 1 0.85 (0.75, 0.97) 0.79 (0.70, 0.90) 0.86 (0.75, 0.97) 0.78 (0.69, 0.89) 0.0008
Model 2 1 0.94 (0.83, 1.07) 0.91 (0.79, 1.03) 0.96 (0.84, 1.09) 0.87 (0.76, 1.00) 0.07
Stroke
No. of case/person-years 149/39,065 135/39,420 107/39,582 142/39,418 119/39,374
Model 1 19 0.92 (0.73, 1.16) 0.71 (0.55, 0.92) 0.93 (0.74, 1.18) 0.72 (0.57, 0.92) 0.03
Model 2 1 0.95 (0.75, 1.20) 0.74 (0.58, 0.96) 0.97 (0.76, 1.22) 0.75 (0.58, 0.96) 0.05

Model 1: Age, sex (men/women), and race (Caucasian/others).

Model 2: Model 1+ diabetes duration (years), BMI at diabetes diagnosis (<23.0, 23.0–24.9, 25.0–29.9, 30.0–34.9, or ≥35.0 kg/m2), physical activity (<3.0, 3.0–8.9, 9.0–17.9, 18.0–26.9, or ≥27.0 MET-h/wk), smoking status (never, past, current 1–14 cigarettes/d, or current ≥15 cigarettes/d), alcohol consumption (0, 0.1–4.9, 5.0–14.9, or ≥15.0 g/d), family history of MI (yes/no), family history of cancer (yes/no), family history of diabetes (yes/no), menopausal status and use of postmenopausal hormones (premenopausal, postmenopausal never users, postmenopausal past users, or postmenopausal current users, only for women), current aspirin use (yes/no), multivitamin use (yes/no), presence of hypertension (yes/no), use of lipid-lowering medication (yes/no), diabetes medication use (insulin, oral medication, or others), intake of total energy (quintiles), and healthy plant-based diet index (quintiles). Mutual adjustment was conducted for dietary glutamine and glutamate. CVD, cardiovascular disease

Abbreviations: MET, metabolic equivalent; MI, myocardial infarction.